Isoliquiritin

Isoliquiritin

SCHEMBL25200366

O=C(/C=C/c1ccc(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1)c1ccc(O)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 3/20 1.00
DPP4 P27487 1/20 1.00
GAA P10253 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
MAPT P10636 3/20 0.60
MAPK1 P28482 3/20 0.60
KDM4E B2RXH2 1/20 0.60
POLB P06746 1/20 0.60
G6PD P11413 1/20 0.60
ADRA1A P35348 1/20 0.60
PTGS2 P35354 1/20 0.60
TYR P14679 3/20 0.59
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
CYP3A4 P08684 3/20 0.55
MEN1 O00255 2/20 0.55
LMNA P02545 2/20 0.55
TP53 P04637 2/20 0.55
HPGD P15428 2/20 0.55
ALOX15 P16050 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoliquiritin SCHEMBL25221453 1.00 AKR1B1 (1.00) AKR1B1DPP4GAATDP1MAPT
Isoliquiritin SCHEMBL25206709 1.00 AKR1B1 (1.00) AKR1B1DPP4GAATDP1MAPT
Isoliquiritin SCHEMBL30382387 1.00 AKR1B1 (1.00) AKR1B1DPP4GAATDP1MAPT
Isoliquiritin SCHEMBL676338 1.00 AKR1B1 (1.00) AKR1B1DPP4GAATDP1MAPT
Isoliquiritin SCHEMBL25201715 1.00 AKR1B1 (1.00) AKR1B1DPP4GAATDP1MAPT
Isoliquiritin SCHEMBL25189174 1.00 AKR1B1 (1.00) AKR1B1DPP4GAATDP1MAPT
Isoliquiritin SCHEMBL25194416 1.00 AKR1B1 (1.00) AKR1B1DPP4GAATDP1MAPT
SCHEMBL25195327 0.96 AKR1B1 (0.92) AKR1B1DPP4GAATDP1MAPT
SCHEMBL25243573 0.96 AKR1B1 (0.92) AKR1B1DPP4GAATDP1MAPT
SCHEMBL25209851 0.95 AKR1B1 (0.90) AKR1B1DPP4GAATDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B AKR1B1 2220/4885DPP4 4226/4885GAA 1372/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 AKR1B1 2215/4885DPP4 3670/4885GAA 1183/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 AKR1B1 2215/4885DPP4 3670/4885GAA 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.